For example, inhibitors targeting PD-1 and PD-L1 have demonstrated significant efficacy in treating melanoma, non-small cell lung cancer, renal cancer, and other solid tumors (43, 44). This evidence concerns the gene CD274 and non-small cell lung carcinoma.